Roger Bergqvist

"It led to the acquisition of Bergman & Beving’s MediTech business, a Nordic distributor of instruments and consumables in the life science sector. MediTech, with roots in Bergman & Beving going back to 1941, provided Addtech with steady, non-cyclical cash flows, and it operated with a decentralized structure. It was a relatively low-risk addition to the portfolio, despite accounting for around 25% of revenue. Roger Bergqvist was very disciplined on price and only paid a 6.5× earnings multiple. When the life science division was later spun off as AddLife in March 2016, it was listed at a market capitalization of nearly SEK 2.1bn ($210m). For Addtech shareholders, this translated into an 11× return over only 11 years—an impressive 28% CAGR."

"Addtech represented the original core industry business area of Bergman & Beving, and the name reflects the company’s original mission: to add value to its customers through expertise in technology. True to its philosophy of nurturing leaders from within, Addtech’s first CEO, Roger Bergqvist, was no stranger to the business."